| __timestamp | Agios Pharmaceuticals, Inc. | Mesoblast Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 19120000 | 54170000 |
| Thursday, January 1, 2015 | 35992000 | 65378000 |
| Friday, January 1, 2016 | 50714000 | 52263000 |
| Sunday, January 1, 2017 | 71124000 | 35072000 |
| Monday, January 1, 2018 | 114145000 | 27415000 |
| Tuesday, January 1, 2019 | 132034000 | 36983000 |
| Wednesday, January 1, 2020 | 149070000 | 50918000 |
| Friday, January 1, 2021 | 121445000 | 63586000 |
| Saturday, January 1, 2022 | 121673000 | 57967000 |
| Sunday, January 1, 2023 | 119903000 | 53107000 |
| Monday, January 1, 2024 | 156784000 | 23626000 |
Data in motion
In the competitive world of biotechnology, managing operational expenses is crucial for sustainability and growth. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Mesoblast Limited and Agios Pharmaceuticals, Inc. over a decade, from 2014 to 2023. Agios Pharmaceuticals, Inc. has seen a significant increase in SG&A expenses, peaking in 2020 with a 680% rise from 2014. Meanwhile, Mesoblast Limited's expenses have fluctuated, with a notable 56% decrease from 2015 to 2018. The data reveals that while Agios has consistently increased its spending, Mesoblast has shown a more variable pattern, possibly indicating different strategic approaches. Notably, 2024 data for Agios is missing, highlighting the need for updated insights. Understanding these trends can provide investors and stakeholders with valuable perspectives on each company's operational efficiency and strategic priorities.
Cost Management Insights: SG&A Expenses for Sanofi and Mesoblast Limited
Operational Costs Compared: SG&A Analysis of Bio-Techne Corporation and Mesoblast Limited
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and Agios Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? CymaBay Therapeutics, Inc. or Agios Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Vericel Corporation vs Agios Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Arrowhead Pharmaceuticals, Inc. and Mesoblast Limited
Operational Costs Compared: SG&A Analysis of Ligand Pharmaceuticals Incorporated and Mesoblast Limited
Mesoblast Limited vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
Breaking Down SG&A Expenses: Agios Pharmaceuticals, Inc. vs Geron Corporation
Mesoblast Limited and BioCryst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Mesoblast Limited vs Evotec SE: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Agios Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.